temozolomide has been researched along with 2,5-bis(5-hydroxymethyl-2-thienyl)furan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B | 1 |
| Barone, D; Capone, F; Cirillo, D; Di Marzo, D; Forte, IM; Giordano, A; Iannuzzi, CA; Indovina, P; Pentimalli, F | 1 |
2 other study(ies) available for temozolomide and 2,5-bis(5-hydroxymethyl-2-thienyl)furan
| Article | Year |
|---|---|
[RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Furans; Glioblastoma; Humans; Temozolomide | 2016 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Furans; Glioblastoma; Humans; Imidazoles; Mutation; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Temozolomide; Tumor Suppressor Protein p53 | 2019 |